Item 5.07. Submission of Matters to a Vote of Security Holders.

On June 22, 2023, at the 2023 Annual Meeting of Stockholders (the "Annual Meeting") of First Wave BioPharma, Inc. (the "Company"), the stockholders voted on the five proposals listed below. The proposals are described in detail in the Company's definitive proxy statement for the Annual Meeting filed with the Securities and Exchange Commission on May 15, 2023 (the "Proxy Statement"). The final results for the votes regarding each proposal are set forth below.

1. The stockholders elected each of James Sapirstein, Edward J. Borkowski,

Charles J. Casamento, Terry Coelho and Alastair Riddell to serve on the
    Company's board of directors for a term of one year expiring at the annual
    meeting of stockholders to be held in 2024 or until their respective
    successors are duly elected and qualified. The tabulation of votes with
    respect to the election of such directors was as follows:




      Nominees         Votes For       Votes Withheld      Broker Non-Votes
James Sapirstein          341,989           77,548               479,278
Edward J. Borkowski       381,741           37,796               479,278
Charles J. Casamento      318,303           101,234              479,278
Terry Coelho              370,182           49,355               479,278
Alastair Riddell          330,357           89,180               479,278

2. The stockholders voted to approve an amendment to the Company's 2020 Omnibus


    Equity Incentive Plan to increase the number of shares of common stock
    authorized for issuance thereunder from 317,480 to 1,167,480 and to increase
    the number of shares that otherwise become available under the plan for grants
    as incentive stock options to 5,000,000. The tabulation of votes with respect
    to this proposal was as follows:




Votes For       Votes Against       Abstentions      Broker Non-Votes
   281,852          136,277             1,408              479,278

3. The stockholders voted to approve, on an advisory basis, the executive


    compensation of the Company's named executive officers as described in the
    Proxy Statement. The tabulation of votes with respect to this proposal was as
    follows:




Votes For       Votes Against       Abstentions      Broker Non-Votes
   286,205          128,673             4,659              479,278

4. The stockholders approved the ratification of the appointment of Mazars USA


    LLP as the Company's independent registered public accounting firm for the
    Company's fiscal year ending December 31, 2023. The tabulation of votes with
    respect to this proposal was as follows:




Votes For       Votes Against       Abstentions
   806,755           64,399             27,661

5. The stockholders approved the adjournment of the Annual Meeting to the extent


    that there were insufficient proxies at the Annual Meeting to approve any one
    or more of the foregoing proposals. The tabulation of votes with respect to
    this proposal was as follows:




Votes For       Votes Against       Abstentions
   718,960          164,471             15,382

Item 9.01. Financial Statements and Exhibits.





  (d) Exhibits.




Exhibit No.   Description
  10.1          Amendment to the 2020 Omnibus Equity Incentive Plan.
104           Cover Page Interactive Data File (embedded within the Inline XBRL
              document).

© Edgar Online, source Glimpses